# CJC-1295 Dosing in Research: What the Studies Administered

> CJC-1295 dosing in research context: human PK studies used 30, 60 or 90 ug/kg single subcutaneous doses; animal work used fixed microgram doses. No established human dose. Every figure cited.

What was given, to which species, at which dose, by which route — reported from the published record. There is no established human dose.

## What the Studies Administered

There is no established human CJC-1295 dose. What exists is a record of what researchers administered, which is a different thing and the only thing this page reports.

The human pharmacokinetic studies used single subcutaneous doses of 30, 60 or 90 ug/kg [1][3]. The GHRH-knockout mouse growth study used 2 ug per dose, given at 24-, 48- or 72-hour intervals, with the once-daily schedule fully normalizing growth and the longer intervals progressively less effective [4]. These are research-context figures — doses chosen to characterize pharmacokinetics and a growth phenotype, not recommendations for any person. Community and clinic 'protocols' for the no-DAC Modified GRF 1-29 and for CJC-1295/ipamorelin commonly cite 100-300 ug fixed doses, but these are not derived from controlled human trials [12].

## Half-Life and Why Duration Depends on the Variant

Duration is set by which variant is in question. The DAC variant's estimated half-life in healthy adults is 5.8 to 8.1 days, and IGF-1 elevation persisted up to 28 days after multiple doses — a single dose acts for days [1]. The no-DAC Modified GRF 1-29 is short-acting, in the minutes-to-hours range, reflecting native GHRH(1-29) clearance slowed by the protease-resistant substitutions [12]. The same nominal 'dose' therefore means very different exposure depending on the form, which is the practical reason the DAC distinction matters for any dosing discussion. The half-life figures sit beside the rest of the variant comparison on the [CJC-1295 DAC vs no-DAC](/dac-vs-no-dac) page.

## Routes Studied and Research Handling

The route studied is subcutaneous injection — the primary route across the human pharmacokinetic literature [1][3] — with intravenous administration used in early GRF(1-29) pharmacokinetic work [12]. Oral bioavailability is negligible, as for any peptide, which is why studies do not administer it orally [12].

In research handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; the four substitutions confer DPP-IV and protease resistance, and DAC conjugation confers the multi-day duration [12]. These notes describe laboratory handling of a research compound, not a human-use instruction.

---

A scroll-told review of the CJC-1295 literature, read top to bottom in the order the evidence accrued — the DAC and no-DAC tracks kept apart, every figure logged to its study and the human gaps left visibly open; no clinic behind the rail and nothing here dispensed or for sale.